Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01486849
Recruitment Status : Completed
First Posted : December 7, 2011
Last Update Posted : May 3, 2019
Sponsor:
Information provided by (Responsible Party):
Cytokinetics

Tracking Information
First Submitted Date  ICMJE November 23, 2011
First Posted Date  ICMJE December 7, 2011
Last Update Posted Date May 3, 2019
Study Start Date  ICMJE November 2011
Actual Primary Completion Date March 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 5, 2011)
Number of participants with adverse events [ Time Frame: approximately 29 days ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01486849 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 29, 2019)
  • Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) [ Time Frame: 22 days ]
    An instrument for evaluating the functional status of patients with ALS. Minimum score is 0 and maximum score is 40. The higher the score the more function is retained. This will be administered at Screening, Day -7, Day 1, Day 15 and Day 22.
  • Change from baseline in scores on tests of maximum handgrip strength and handgrip fatigue [ Time Frame: 22 days ]
    Measured using the DynEx Electronic Hand Dynamometer. Patients asked to squeeze the device with the maximum possible force to establish the maximum voluntary contraction. Handgrip fatigue is then measured. Patient is asked to squeeze the device until they can no longer stay above 60% of target or 120 seconds. This will be measured at Screening, Day -7, Day 1, Day 15 and Day 22.
  • Change from baseline in scores on tests of muscle strength [ Time Frame: 22 days ]
    Muscle strength is measured using Hand Held Dynamometry. A series of assessments are done on different muscle groups. This will be measured at Day -7, Day 1, and Day 22.
  • Change from baseline in scores on tests of Timed Up and Go [ Time Frame: 22 days ]
    TUG is measured by timing how long it takes for a subject to stand up from a chair, walk 10 feet, turn around, walk back to the chair and sit down. This will be measured at Day -7, Day 1, and Day 22.
  • Change from baseline in scores on tests of Sniff Nasal Inspiratory Pressure (SNIP) [ Time Frame: 22 days ]
    SNIP will be measured using the Micro Medical Respiratory Pressure Meter (MicroRPM) at Screening, Day -7, Day 1, Day 15 and Day 22.
  • Change from baseline in scores on tests of Slow Vital Capacity (SVC) [ Time Frame: 22 days ]
    SVC will be measured using the ndd EasyOne Spirometer System at Screening, Day -7, Day 1, Day 15 and Day 22.
  • Change from baseline in scores on tests of Maximum Voluntary Ventilation (MVV) [ Time Frame: 21 days ]
    MVV will be measured using the EasyOne Spirometer System at Screening, Day -7, Day 1, Day 15 and Day 22.
  • Change from baseline in Patient Global Assessment [ Time Frame: 22 days ]
    Patients will be asked to assess whether they feel the same, better or worse as compared to how they felt at pre-dose on Day 1
  • Change from baseline in Investigator Global Assessment [ Time Frame: 22 days ]
    Investigator will assess whether the patient appears the same, better or worse as compared to the patient's status at pre-dose on Day 1.
  • Evaluate the pharmacokinetics of CK-2017357 [ Time Frame: Day 1, Day 15, and Day 22 ]
    Plasma levels of CK-2017357 will be measured at pre-dose, and at 2 and 4 hours post AM dose
  • Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357 [ Time Frame: Day 1, Day 15, and Day 22 ]
    Plasma levels of riluzole will be measured at pre-dose and at 2 and 4 hours post AM dose
Original Secondary Outcome Measures  ICMJE
 (submitted: December 5, 2011)
  • Change from baseline in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) [ Time Frame: 21 days ]
  • Change from baseline in scores on tests of muscle fatigue (handgrip fatigue, muscle strength, and timed up and go test) [ Time Frame: 21 days ]
  • Change from baseline in scores on tests of pulmonary function (Sniff Nasal Inspiratory Pressure [SNIP], Slow Vital Capacity [SVC] and Maximum Voluntary Ventilation [MVV]) [ Time Frame: 21 days ]
  • Change from baseline in Patient Global Assessment [ Time Frame: 21 days ]
  • Change from baseline in Investigator Global Assessment [ Time Frame: 21 days ]
  • Evaluate the pharmacokinetics of CK-2017357 [ Time Frame: Day 1, Day 15, and Day 22 ]
  • Evaluate the pharmacokinetics of riluzole in patients receiving CK-2017357 [ Time Frame: Day 1, Day 15, and Day 22 ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Official Title  ICMJE A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Brief Summary A Phase II, double-blind, randomized, placebo-controlled ascending dose titration study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple ascending doses of CK-2017357 to an individual patient maximum tolerated dose (MTD), using a within-patient twice daily (BID) dose-titration regimen in ALS patients on 50 mg riluzole once daily (QD).
Detailed Description

Patients will be randomized to one of two dosing groups, active CK-2017357 or placebo, in a 3:1 ratio. Prior to study drug dosing, patients will be required to decrease their riluzole dose to 50 mg QD for 7 days; after this 7 day period patients will either receive placebo or start the titration on active CK-2017357 while continuing to take riluzole at 50 mg QD.

Potential patients will be screened to assess their eligibility to enter the study within 21 days prior to Day -7, when they will begin taking riluzole at the decreased dose of 50 mg QD. Patients will be randomized in a 3:1 ratio to CK-2017357 (Group 1) or placebo (Group 2). On Day 1, patients will begin taking a total daily dose of 250 mg (125 mg BID) of CK-2017357 or matching placebo tablets BID for 7 days. Then they will take a total daily dose of 375 mg (125 mg morning [AM] and 250 mg evening [PM]) of CK-2017357 or matching placebo tablets BID for 7 days, and finally, they will take a total daily dose of 500 mg (250 mg BID) of CK-2017357 or matching placebo tablets BID for 7 days. A final dose of 250 mg of CK-2017357 or placebo will be taken in the morning on Day 22 at the study site.

Dose-escalation of CK-2017357 or placebo may be stopped, or the dose reduced to a lower level, based on tolerability. All patients who return to a lower dose will stay on that dose for the remainder of the study.

Patients will remain on the decreased dose of riluzole until the follow-up visit approximately 7 days after Day 22.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Amyotrophic Lateral Sclerosis
Intervention  ICMJE
  • Drug: CK-2017357
    Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
    Other Name: tirasemtiv
  • Drug: Placebo
    Matching placebo tablets BID for 21 days
  • Drug: Riluzole 50 MG
Study Arms  ICMJE
  • Experimental: Dose Titration of CK-2017357 (Group 1)
    Dose titration of active drug as add-on therapy to riluzole
    Interventions:
    • Drug: CK-2017357
    • Drug: Riluzole 50 MG
  • Placebo Comparator: Matching Placebo (Group 2)
    Placebo as add-on therapy to riluzole
    Interventions:
    • Drug: Placebo
    • Drug: Riluzole 50 MG
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 29, 2019)
27
Original Estimated Enrollment  ICMJE
 (submitted: December 5, 2011)
24
Actual Study Completion Date  ICMJE March 2012
Actual Primary Completion Date March 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Able to comprehend and willing to sign an Informed Consent Form (ICF)
  2. Males or females 18 years of age or older
  3. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria)
  4. Maximum voluntary grip strength in at least one hand between 10 & 40 pounds (females) and 10 & 60 pounds (males)
  5. Able to swallow tablets with water
  6. Currently taking and tolerating a stable dose of 50 mg BID riluzole
  7. Willing and able to reduce daily dose of riluzole to 50mg QD for 5 weeks
  8. Not currently taking or willing and able to remain off theophylline-containing medications during study participation
  9. Patient has a caregiver who is capable of observing and reporting patient status
  10. Upright Slow Vital Capacity (SVC) >50% of predicted for age, height, and sex
  11. Able to perform pulmonary function tests

Exclusion Criteria:

  1. Life expectancy <3 months
  2. Receipt of investigational study drug within 30 days or 5 half-lives of the prior agent, whichever is greater, prior to dosing
  3. Any prior treatment with CK-2017357
  4. Any use of non-invasive positive pressure ventilation (NIPPV), such as Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP)

Other protocol-defined inclusion/exclusion criteria may apply.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01486849
Other Study ID Numbers  ICMJE CY 4025
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Cytokinetics
Study Sponsor  ICMJE Cytokinetics
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Jeremy Shefner, MD, PhD State University of New York - Upstate Medical University
PRS Account Cytokinetics
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP